linjc16/ctgov huggingface dataset:
LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to describe the results of Lateral Pharyngoplasty in the treatment of snore and OSAS.

Official Title
-----------------
LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA

Conditions
-----------------
Snore, Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Procedure: Lateral Pharyngoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: snore osas Exclusion Criteria: previous pharynx surgery use of medication that modifies the muscular tonus or the perception of sleepiness before or after the surgery body mass index (BMI) bigger than 35 kg/m2 neurological or psychiatric disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AHI | Change in AHI | 6 months |
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Conditions
-----------------
Colorectal Neoplasms

Intervention / Treatment
-----------------
* Drug: tezacitabine
* Drug: oxaliplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy. Patients must have at least one measurable tumor. Patients may not have received prior treatment with oxaliplatin.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tezacitabine|nan|
|Drug: oxaliplatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

Official Title
-----------------
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Conditions
-----------------
Normal PBPC Donors

Intervention / Treatment
-----------------
* Drug: filgrastim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Eligible to be PBPC donor for allogeneic transplantation as determined by local institution Exclusion Criteria: - History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Filgrastim<br>Normal donors being treated with filgrastim for PBPC mobilization and collection | Drug: filgrastim<br>* Normal donors being treated with filgrastim for PBPC mobilization and collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spleen fold change measured by ultrasound |  | Before, during, and through 1 week post-PBPC mobilization and collection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spleen change associations with filgrastim dose and hematologic variables |  | Before, during, and through 1 week post-PBPC mobilization and collection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
normal PBPC donors
A Low Glycemic Load Diet During Pregnancy in Overweight Women

Study Overview
=================
Brief Summary
-----------------
This study will compare the effects of a low glycemic load versus standard diet for pregnancy on outcomes related to risk for obesity, diabetes, and heart disease in both mother and infant.

Official Title
-----------------
Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women

Conditions
-----------------
Overweight, Pregnancy

Intervention / Treatment
-----------------
* Behavioral: Low glycemic load
* Behavioral: Low fat diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with prepregnant or first trimester BMI equal to or greater than 25 kg/m2 and less than 45 kg/m2 Singleton pregnancy Willing to consume the diets for duration of pregnancy Participant to be at week 28 or less of pregnancy at baseline visit Exclusion Criteria: Smoking during pregnancy Major medical illness (e.g., diabetes mellitus, hypertension, thyroid disease) Patients taking prescription medication known to affect body weight Alcohol consumption during pregnancy Patients who declare their intention to deliver infants in the environment outside of Beth Israel Deaconess Medical Center, Boston High level of physical activity

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Low glycemic load diet | Behavioral: Low glycemic load<br>* Provision of foods and dietary counseling to promote a low glycemic load diet<br>|
| Active Comparator: 2<br>Low fat diet | Behavioral: Low fat diet<br>* Provision of foods and dietary counseling to promote a low fat diet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Birth weight as assessed by z-scores |  | At birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal energy intake |  | During pregnancy | 
| Maternal weight gain |  | During pregnancy | 
| Maternal insulin resistance assessed by HOMA |  | During pregnancy | 
| Maternal metabolic syndrome components |  | During pregnancy | 
| Infant body composition (ponderal index, skinfold thickness) |  | At birth | 
| Cord blood glucose |  | At birth | 
| cord blood insulin |  | At birth | 
| cord blood leptin |  | At birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycemic index, Glycemic load, Low fat, Impaired glucose tolerance, Large for gestational age infant, Excessive body weight
Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis

Study Overview
=================
Brief Summary
-----------------
The purpose of ths study is to evaluate changes in life quality of patients affected by rhinoconjuntivitis with or without asthma after immunotherapy treatment. It is an observational, prospective and comparative study before-after immunotherapy treatment with a one year follow-up.

Official Title
-----------------
Prospective Study for Evaluating Life Quality and Its Determinant Factors as Treatment Adherence and Immunotherapy Satisfaction in Patients With Rhinoconjunctivitis With or Without Asthma, Sensitized at Least to One Aeroallergen

Conditions
-----------------
Allergic Rhinoconjunctivitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Based on Routine Clinical Practice Inclusion criteria: Patients affected by allergic rhinoconjunctivitis sensityzed to one or several aeroallergens.Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild concomitant asthma is allowed (GINA 2013) Patients older than 12 years old Patients being subsidiaries of receiving allergen immunotherapy treatment Patients who obtained a prick test result ≥ 3 mm diameter to any aeroallergen. Positive and negative control of the test should give consistent results. Patients with specific immunoglobulin E ≥ class 2 (CAP/PHADIA) to any aeroallergen. Exclusion criteria (based on routine clinical practice): Patients with severe asthma or forzed expiratoy volumen in 1 second FEV1< 70% even if the are pharmacologically controlled . Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator seems relevant so as to interfere with the treatment. Patients with a previous history of anaphylaxis Patients under treatment with tricyclic antidepressives, phenothiazines , β-blockers, or Angiotensin Converting Enzyme Inhibitors (ACEI) Female patients who are pregnant or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Life Quality as measured by RQLQ questionaire (≥12years) |  | One Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence as measured by patient diary |  | One Year | 
| Treatment Satisfaction as measured by visual analogue scale |  | One Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergy, Allergic rhinoconjunctivitis, Immunotherapy, Life Quality, Adherence
Developing Objective Fatigue Indicators in Colorectal Cancer Survivors.

Study Overview
=================
Brief Summary
-----------------
The aims of this four-year study are to Explore exercise behavior, exercise barriers, and identify the significant factors for exercise behavior in colorectal cancer survivors. Explore the relationships among fatigue, muscle strength, and metabolomics and further examine the possible biomarkers from muscle strength and metabolomics for fatigue. Develop a clinical guidelines of home-based fatigue management and exercise program and test its effect on decreasing fatigue for patients with colorectal cancer after surgery in Taiwan.

Official Title
-----------------
Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Behavioral: exercise education and walking program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal cancer survivors completed treatment at least 3 months in clinics. Aged above 20. Exclusion Criteria: KPS < 60 Stage 4 Bone meta

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise education and walking program<br> | Behavioral: exercise education and walking program<br>* 12-week moderate intensity walking program<br>|
| No Intervention: maintain their daily activity<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors | Develope the clinical exercise education program guideline for patients with early stage colorectal cancer survivor. | four-year study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer、Fatigue、Muscle strength、Metabolomics
Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.

Study Overview
=================
Brief Summary
-----------------
A phase Ⅲ, multi-center, randomized, double-blinded, placebo and active comparator clinical trial to assess the efficacy and safety of combination therapy of Motireb 5/100 mg in functional dyspepsia patients.

Conditions
-----------------
Functional Dyspepsia

Intervention / Treatment
-----------------
* Drug: Motireb 5/100 mg
* Drug: Mosapride citrate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female aged 19 years or older Patient with functional dyspepsia met the ROME III criteria or symptom assessment form Exclusion Criteria: Patient with peptic ulcer or gastroesophageal reflux disease Patients with previous gastrointestinal surgery Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation Patients with history of gastrointestinal cancer Patients with pancreatic disease (pancreatitis, pancreatic cancer, etc), biliary disease, inflammatory bowel disease, acute gastritis. Patients with Zollinger-Ellison syndrome Patients with irritable bowel syndrome Pregnant or lactating women Patients with hepatic abnormality Patients with renal dysfunction or chronic kidney disease Patients who are judged by the investigators to be unsuitable to participate in the clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motireb 5/100 mg t.i.d<br>Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d | Drug: Motireb 5/100 mg<br> <br> |
| Active Comparator: Mosapride citrate t.i.d<br>Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d | Drug: Mosapride citrate<br> <br> |
| Placebo Comparator: Placebo t.i.d<br>Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The responder ratio of GOS(Global Overall Symptom) |  | at the 4th week |
Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation

Study Overview
=================
Brief Summary
-----------------
The present study will evaluate the long term effects on scar formation for dermatome-induced skin wounds treated with Collagenase Santyl® Ointment or vehicle (white petrolatum ointment) alone. The previous study, 017-101-09-001, utilized a small, experimental, cutaneous wound to evaluate both time to complete wound closure and quality of the resulting scar when Collagenase Santyl® Ointment was used to treat the wound.

Official Title
-----------------
A Long Term Follow-Up to Study 017-101-09-001: Effect of Collagenase Santyl® Ointment vs. Placebo on Healing and Scarring Characteristics of 600um Dermatome Wounds

Conditions
-----------------
Follow up to Acute Wound Scar Study

Intervention / Treatment
-----------------
* Biological: Santyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects will be considered qualified for enrollment if they participated in the Collagenase Santyl® Ointment Study 017 101-09-001 and provide written informed consent. The informed consent document must be read, signed, and dated by the suubject before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject. A photocopy of the signed informed consent document must be provided to the subject and the original signed document placed in the subject's chart. Subject participated in the 017-101-09-001 study and received at least one application of a test article, whether Collagenase Santyl® Ointment or White Petrolatum. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Assessment<br>All subjects will receive same assessments. | Biological: Santyl<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar Assessment | Vancouver Scar Scale assessment of dermatome wounds previously treated with Santyl Ointment or White Petrolatum | 1 Day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar Quality | Quality of scars over time will be assessed with the BTC-2000 instrument assessment | 1 Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Collagen, collagenase, scar
Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
An international multicenter observation study to evaluate the diagnostic accuracy and predictive value of ultrasound using the IDEA terminology in the detection of deep endometriosis in women scheduled for surgery.

Official Title
-----------------
Ultrasound Evaluation of the Pelvis Using the International Deep Endometriosis Analysis (IDEA) Terminology in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery - IDEA 1 Study

Conditions
-----------------
Endometriosis Rectovaginal Septum, Endometriosis of Bladder, Surgery, Gynecologic Disease, Endometriosis, Endometriosis, Rectum, Endometriosis of Colon, Endometriosis of Vagina

Intervention / Treatment
-----------------
* Procedure: Ultrasound evaluation of DE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for radical laparoscopic endometriosis surgery Exclusion Criteria: <18 years >45 years (suspected) Pelvic malignancy for example gynecological, intestinal or urological malignancy Premenarche Menopause Pregnancy Patients refusal for radical surgery (for example refusal for bowel resection/temporary stoma) Surgery performed more than 1 year after ultrasound scan Patients refusal to participate to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of deep endometriosis | The primary objective is to assess the diagnostic value of the ultrasound features in the diagnosis of deep endometriosis. The endpoints are the univariable diagnostic accuracies of ultrasound features (defined by the IDEA consensus statement) for the presence of deep endometriosis at any location: anterior compartment (i.e. bladder and its specific location) or posterior compartment (i.e. rectovaginal septum, uterosacral ligaments, torus uterinus, vaginal fornix and bowel involvement). All recruited patients are included in this analysis. The reference standard for this objective is whether there is deep endometriosis (at any location) or not (binary outcome). | 1 year |